RE:Competition is at the door Without a doubt, Otleanu007 is the biggest nimrod on this board. Friend, you need to read with your eyes open before trying to scare SZLS investors. We are a bit smarter than you. Nice try though. They are not at the door, they are not even in the same zip code. Allow me to show you how dim your bulb is.
The data suggest Exact Sciences has a shot at competing with the likes of Grail and Guardant Health for the liquid biopsy market, although management acknowledged it still has "a ton of work" to do.
Some of that work will focus on improving the ability of the test to detect early-stage cancer. Most of the samples tested by Exact Sciences were from late-stage cancer patients but the big opportunity, and more demanding challenge, is finding tumors before they spread. Olteanu007 wrote:
Exact Sciences wows investors with preliminary multi-cancer liquid biopsy data. https://www.medtechdive.com/news/exact-sciences-wows-investors-with-multi-cancer-liquid-biopsy-data/585881/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202020-09-25%20MedTech%20Dive%20%5Bissue:29884%5D&utm_term=MedTech%20Dive